GRI Bio IncNASDAQ:GRINASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7390
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.7390
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GRI |
|---|---|---|
| 09:32 ET | 5889 | 0.6801 |
| 09:33 ET | 584 | 0.6712 |
| 09:35 ET | 1900 | 0.6888 |
| 09:37 ET | 1200 | 0.6819 |
| 09:39 ET | 8200 | 0.6819 |
| 09:42 ET | 2900 | 0.6819 |
| 09:44 ET | 100 | 0.681416 |
| 09:46 ET | 224 | 0.672 |
| 09:48 ET | 100 | 0.6819 |
| 09:51 ET | 900 | 0.68 |
| 09:53 ET | 5699 | 0.6759 |
| 09:57 ET | 100 | 0.6759 |
| 10:04 ET | 1200 | 0.68215 |
| 10:06 ET | 2303 | 0.6888 |
| 10:08 ET | 800 | 0.6888 |
| 10:13 ET | 450 | 0.68 |
| 10:15 ET | 5250 | 0.6888 |
| 10:20 ET | 2000 | 0.6757 |
| 10:26 ET | 100 | 0.6887 |
| 10:33 ET | 1324 | 0.678557 |
| 10:38 ET | 1500 | 0.68 |
| 10:40 ET | 200 | 0.6884 |
| 10:44 ET | 1550 | 0.682 |
| 10:45 ET | 2192 | 0.6884 |
| 10:47 ET | 3600 | 0.6884 |
| 10:58 ET | 816 | 0.6763 |
| 11:02 ET | 22447 | 0.699 |
| 11:03 ET | 1650 | 0.699 |
| 11:05 ET | 1100 | 0.699 |
| 11:07 ET | 200 | 0.699 |
| 11:12 ET | 822 | 0.69 |
| 11:14 ET | 600 | 0.699 |
| 11:18 ET | 100 | 0.698 |
| 11:20 ET | 2528 | 0.6838 |
| 11:21 ET | 340 | 0.6983 |
| 11:38 ET | 100 | 0.69 |
| 11:39 ET | 2429 | 0.694426 |
| 11:41 ET | 12308 | 0.698 |
| 11:43 ET | 700 | 0.6983 |
| 11:45 ET | 10134 | 0.7039 |
| 11:48 ET | 22426 | 0.7081 |
| 11:50 ET | 493 | 0.7081 |
| 11:52 ET | 500 | 0.7082 |
| 11:54 ET | 150 | 0.7085 |
| 11:56 ET | 1550 | 0.7085 |
| 11:57 ET | 274 | 0.7 |
| 12:01 ET | 6350 | 0.700101 |
| 12:08 ET | 200 | 0.7001 |
| 12:14 ET | 674 | 0.7057 |
| 12:15 ET | 457 | 0.709 |
| 12:21 ET | 600 | 0.709 |
| 12:26 ET | 500 | 0.705 |
| 12:28 ET | 100 | 0.7 |
| 12:35 ET | 700 | 0.7057 |
| 12:39 ET | 1300 | 0.709 |
| 12:51 ET | 3119 | 0.71 |
| 01:11 ET | 200 | 0.71 |
| 01:13 ET | 1081 | 0.7132 |
| 01:15 ET | 400 | 0.71 |
| 01:22 ET | 665 | 0.7083 |
| 01:36 ET | 1754 | 0.7083 |
| 01:38 ET | 743 | 0.709 |
| 01:44 ET | 5990 | 0.709 |
| 01:49 ET | 4447 | 0.7051 |
| 01:58 ET | 2937 | 0.7 |
| 02:02 ET | 500 | 0.7099 |
| 02:14 ET | 650 | 0.7 |
| 02:16 ET | 3537 | 0.7051 |
| 02:18 ET | 7327 | 0.7165 |
| 02:27 ET | 160 | 0.7165 |
| 02:30 ET | 134 | 0.728 |
| 02:32 ET | 400 | 0.72 |
| 02:34 ET | 3876 | 0.706281 |
| 02:39 ET | 1000 | 0.706301 |
| 02:57 ET | 120 | 0.723001 |
| 02:59 ET | 10358 | 0.7395 |
| 03:03 ET | 500 | 0.7394 |
| 03:14 ET | 1793 | 0.7395 |
| 03:19 ET | 670 | 0.7101 |
| 03:21 ET | 721 | 0.710301 |
| 03:24 ET | 378 | 0.7103 |
| 03:33 ET | 1590 | 0.7103 |
| 03:44 ET | 9357 | 0.7395 |
| 03:53 ET | 1800 | 0.7395 |
| 03:55 ET | 135 | 0.7394 |
| 03:57 ET | 4500 | 0.72445 |
| 04:00 ET | 2500 | 0.739 |
Nov 21, 2024
Nov 14, 2024
*DJ GRI Bio 9-Mos Loss $6.3M >GRI, from 4:26PM ET on Thursday Nov 14, 2024 by Dow Jones
4:26PM ET on Thursday Nov 14, 2024 by Dow JonesGRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis, from 4:20PM ET on Thursday Nov 14, 2024 by Dow Jones
4:20PM ET on Thursday Nov 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
GRI Bio Inc | 6.2M | 0.0x | --- |
CNS Pharmaceuticals Inc | 6.2M | 0.0x | --- |
Viracta Therapeutics Inc | 6.3M | -0.1x | --- |
Agentix Corp | 6.0M | -20.3x | --- |
Alzamend Neuro Inc | 5.9M | -0.1x | --- |
Alterola Biotech Inc | 5.8M | -2.4x | --- |
Company Information
GRI Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Its therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as an oral therapeutic for the treatment of idiopathic pulmonary fibrosis (IPF). Its product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. The Company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) or lupus and multiple sclerosis (MS).
Contact Information
- Headquarters
- 2223 Avenida De La Playa, Suite 208LA JOLLA, CA, United States 92037
- Phone
- 619-400-1171
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- David Szekeres
- President, Chief Executive Officer, Director
- W. Marc Hertz
- Chief Financial Officer
- Leanne Kelly
- Chief Scientific Officer
- Vipin Chaturvedi
- Chief Medical Officer
- Albert Agro
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 8.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -2.02 |
EPS | $-54.21 |
Book Value | $5.21 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
